ECG
CTIC

EPIQ Capital Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

EPIQ Capital Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-120,939
Closed -$357K – 65
2021
Q3 		$357K Buy
+120,939
New +$329K 0.04% 49

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

EPIQ Capital Group's CTIC Position: Q4 2021 in Review

EPIQ Capital Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2021, closing a stake of 120,939 shares — an estimated $357K sold.

EPIQ Capital Group first reported a position in CTIC in Q3 2021 and held it in 1 quarter. The position peaked at $357K in Q3 2021. 63 funds tracked by Wall St. Rank hold CTIC as of Q4 2021.

  • EPIQ Capital Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2021 after selling out during the quarter.
  • EPIQ Capital Group sold 120,939 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2021, an estimated $357K.
  • EPIQ Capital Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2021 and held it in 1 quarter.
  • EPIQ Capital Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $357K in Q3 2021.
  • 63 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2021.

Based on EPIQ Capital Group's 13F filing for Q4 2021, filed 9 Feb 2022.